PapersFlow Research Brief
vaccines and immunoinformatics approaches
Research Guide
What is vaccines and immunoinformatics approaches?
Vaccines and immunoinformatics approaches refer to computational methods in immunoinformatics that predict peptide-MHC binding affinity, epitope prediction, and related processes to support vaccine design against pathogens and tumors.
This field encompasses 35,967 papers on antigen presentation, HLA class I and II molecules, bioinformatics tools for T-cell and B-cell epitope prediction, and proteasomal cleavage. It focuses on predicting peptide-MHC binding affinity to identify immunogenic epitopes for vaccines. Growth data over the past 5 years is not available.
Topic Hierarchy
Research Sub-Topics
Peptide-MHC Binding Prediction
This sub-topic develops machine learning models like NetMHC for predicting binding affinities between peptides and MHC molecules. Researchers focus on allele-specific accuracy and pan-specific predictors.
T-Cell Epitope Prediction
This sub-topic covers computational tools integrating proteasomal cleavage, TAP transport, and MHC presentation for CD8+ T-cell epitopes. Researchers benchmark immunogenicity classifiers.
B-Cell Epitope Prediction
This sub-topic examines linear and conformational epitope mapping using sequence and structure-based methods for antibody recognition. Researchers study solvent accessibility and flexibility features.
HLA Class I and II Allele-Specific Modeling
This sub-topic builds specialized predictors for diverse HLA alleles crucial for population coverage in vaccine design. Researchers address binding motifs and polymorphism effects.
Immunoinformatics Tools for Vaccine Design
This sub-topic develops integrated platforms like IEDB and VaxiJen combining multiple epitope prediction pipelines. Researchers validate reverse vaccinology workflows.
Why It Matters
Immunoinformatics approaches enable epitope prediction for vaccine design, as shown in clinical trials where gp100 peptide vaccine combined with ipilimumab improved overall survival in patients with previously treated metastatic melanoma (Hodi et al., 2010). In HIV prevention, the ALVAC-HIV and AIDSVAX B/E vaccine regimen reduced HIV infection risk by a modest amount in a community-based population with largely heterosexual risk (Rerks-Ngarm et al., 2009). Targets of T cell responses to SARS-CoV-2 identified through such methods help map immune epitopes in COVID-19 patients and unexposed individuals (Grifoni et al., 2020). These applications demonstrate how epitope prediction supports vaccines for melanoma, HIV, and coronaviruses.
Reading Guide
Where to Start
"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma" by Hodi et al. (2010), as it provides a clinical example of peptide vaccine use with immunotherapy, introducing epitope-based vaccine outcomes.
Key Papers Explained
"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma" (Hodi et al., 2010) shows gp100 peptide vaccine efficacy in melanoma, building on foundational antigen presentation by dendritic cells in "The Dendritic Cell System and its Role in Immunogenicity" (Steinman, 1991). Cancer immunoediting concepts from "Cancer immunoediting: from immunosurveillance to tumor escape" (Dunn et al., 2002) explain tumor escape from epitope-targeted vaccines. SARS-CoV-2 epitope mapping in "Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals" (Grifoni et al., 2020) extends these to viral vaccines.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research continues on SARS-CoV-2 variants and immune escape, as in "SARS-CoV-2 variants, spike mutations and immune escape" (Harvey et al., 2021), focusing on mutation impacts on epitope prediction. HIV vaccine trials like "Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand" (Rerks-Ngarm et al., 2009) highlight modest efficacy, pointing to needs in multi-epitope design.
Papers at a Glance
Frequently Asked Questions
What is peptide-MHC binding prediction in immunoinformatics?
Peptide-MHC binding prediction identifies peptides that bind to HLA class I or II molecules for antigen presentation. This supports epitope prediction for T-cell responses in vaccine design. Tools in immunoinformatics analyze binding affinity to select vaccine candidates.
How do immunoinformatics tools aid vaccine design?
Immunoinformatics tools predict T-cell and B-cell epitopes by modeling proteasomal cleavage and MHC binding. They enable rapid identification of immunogenic sequences from pathogens like SARS-CoV-2. This accelerates vaccine development as seen in mapping T cell targets (Grifoni et al., 2020).
What role do dendritic cells play in immunogenicity related to vaccines?
Dendritic cells function as antigen-presenting cells that initiate MHC-restricted T cell sensitization and T-dependent antibody formation. They are found in nonlymphoid tissues and drive immune responses to vaccines. Steinman (1991) describes their system-wide role in immunogenicity.
Why study T-cell epitopes in SARS-CoV-2 vaccine design?
T-cell epitopes from SARS-CoV-2 are targets of immune responses in COVID-19 patients and unexposed individuals. Grifoni et al. (2020) identified these epitopes, informing vaccine strategies. Such data guides immunoinformatics predictions for broad protection.
What is the current state of immunoinformatics paper output?
The field includes 35,967 works focused on epitope prediction and vaccine design. Topics cover HLA molecules, bioinformatics tools, and antigen presentation. No 5-year growth rate is reported.
Open Research Questions
- ? How can immunoinformatics improve prediction accuracy for rare HLA alleles in diverse populations?
- ? What are the key proteasomal cleavage sites that limit epitope availability for T-cell vaccines?
- ? How do SARS-CoV-2 spike mutations affect predicted MHC binding and immune escape in vaccines?
- ? Which bioinformatics tools best integrate B-cell and T-cell epitope predictions for multi-epitope vaccines?
Recent Trends
The field maintains 35,967 papers with no reported 5-year growth rate.
Recent highly cited works emphasize SARS-CoV-2 applications, including T-cell epitope targets (Grifoni et al., 2020, 3960 citations) and spike mutation effects on immune escape (Harvey et al., 2021, 3740 citations).
No preprints or news from the last 12 months are available.
Research vaccines and immunoinformatics approaches with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching vaccines and immunoinformatics approaches with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers